The 2020 China Lung Cancer Prevention and Control Summit Forum was held in Beijing to help improve the five-year survival rate of lung cancer.

On September 11, 2020, in response to the call for "Healthy China Action (2019-2030) Cancer Prevention and Control Action", the 2020 China Lung Cancer Prevention summit forum, hosted by the Beijing Bethun Public Welfare Foundation and co-sponsored by People's Network People's Health, was successfully held in Beijing on September 11.
Forum aims to popularize the knowledge of lung cancer prevention and treatment, enhance the awareness of early diagnosis and treatment of lung cancer, and help to continuously improve the overall five-year survival rate of lung cancer patients in China, to help "Healthy China 2030" goal.
According to the statistics of the 2019 National Cancer Report released by the National Cancer Center, the annual incidence of lung cancer in China is as high as 784,000, and the morbidity and mortality rate of lung cancer account for 20.03% and 26.99% of all malignant tumors, respectively.
This forum focuses on the current situation of lung cancer diseases in China and the progress of diagnosis and treatment, based on practical, forward-looking and innovative, from lung cancer prevention and treatment to strengthen the awareness of early screening, the progress of precision treatment of lung cancer, improve the accessability of innovative drugs three dimensions to carry out relevant academic discussions.
Forum attracted a total of including Beijing Bethun Public Welfare Foundation Honorary Vice President Chen Shaobo, People's Network Deputy Editor-in-Chief, People's Health Chairman Sun Haifeng, Vice President of the Chinese Academy of Medical Sciences Oncology Hospital Gao Shuxuan, China Center for Disease Control and Prevention Slow Disease Center Director Wu Jing, National Cancer Center cancer early diagnosis and treatment Researcher Li Ni, Deputy Director of the Office, Gu Xuefei, Director of the Medical Security Research Office of the Health Development Research Center of the National Health and Health Commission, Professor Wu Yilong, Life Director of Guangdong Provincial People's Hospital, An expert in the field of lung cancer, Professor Wang Yan, Chief Physician of oncology Hospital of the Chinese Academy of Medical Sciences, and nearly 100 clinical elites, experts and scholars participated.
The malignant tumor is one of the most important causes of death among the residents of our country, and the morbidity and mortality of lung cancer rank first among malignant tumors, " Gao Shuxuan, vice president of the Oncology Hospital of the Chinese Academy of Medical Sciences, said in his speech.
this forum focus on lung cancer prevention and treatment, is of great significance.
strengthen cancer prevention and treatment, focusing on prevention, the need to effectively implement early detection of cancer, early diagnosis, early treatment.
to improve the five-year survival rate of lung cancer needs a lot of help.
development of precision treatment of lung cancer can help to improve the survival rate and quality of life of lung cancer patients.
with the adjustment of the national health insurance directory, more and more high-quality innovative drugs are included in health insurance, which is a boon for lung cancer patients.
to improve access to innovative medicines, we need not only health insurance, but also commercial insurance, public welfare funds and many other ways to help.
china's cancer prevention and treatment work after many years of development, has achieved remarkable results, cancer patients overall five-year survival rate compared with the past significantly improved, the quality of life of patients has also been greatly improved.
"In July last year, the State Council issued the Opinions of the State Council on the Implementation of the Healthy China Action, which proposed the "Implementation of Cancer Prevention and Control Action" to advocate active prevention of cancer and promote the prevention of lung cancer. Early screening, early diagnosis, early treatment, reduce cancer morbidity and mortality, improve the quality of life of patients, proposed by 2022 and 2030, the overall five-year survival rate of cancer is not less than 43.3 percent and 46.6 percent, respectively.
Wu Jing, director of the Cdc's Center for Chronic Diseases, said that the Outline of the "Healthy China 2030" program proposes that by 2030, the overall five-year survival rate of cancer will be increased by 15% in order to achieve the health management of chronic diseases in the whole population and throughout the life cycle.
the improvement of cancer prevention, screening, early diagnosis and treatment, and standardized diagnosis and treatment will help to curb the increase in cancer incidence and mortality."
the key to prevention and control of chronic diseases such as cancer, Director Wu Jing pointed out that "everyone is the first person responsible for their own health."
take the initiative to take early measures to strengthen prevention, practice a healthy lifestyle, regular anti-cancer check-ups, pay close attention to cancer red flags, receive standardized treatment is the key to lung cancer prevention and control.
post-epidemic era, infectious disease prevention and control and slow disease prevention and control can not be completely separated, we must strengthen the outbreak of chronic disease patients, including cancer patients attention and continuous care.
"Lung cancer prevention and treatment is a common challenge for China and the world, and screening and early diagnosis and treatment are one of the most effective means to reduce lung cancer deaths," said Researcher Li Ni, deputy director of the Office of Early Diagnosis and Treatment of Cancer at the National Cancer Center, in a speech.
screening program based on multi-center population in China, organized by the National Cancer Center, confirms that screening and early diagnosis and treatment can effectively improve the early detection of lung cancer in China, thereby improving survival and reducing death.
At present, the state attaches great importance to cancer screening and early diagnosis and treatment, including lung cancer, the implementation of a series of cancer prevention and control policies, cancer screening and early diagnosis and treatment into the country's major public health services; Screening of 400,000 people at high risk of lung cancer, and actively build a national cancer prevention and control platform, under the leadership of the Director of the National Cancer Center, He Jie academician, to serve China's cancer prevention and control strategic planning steady progress;
" National Cancer Center Cancer Early Diagnosis and Early Treatment Office Deputy Director Li Ni researcher precision treatment to help improve the survival rate of lung cancer patients 5 years of current common treatment methods for lung cancer include surgery, radiotherapy, chemotherapy, targeted treatment, immunotherapy, among them, the emergence of targeted treatment has ushered in a new era of precision treatment of lung cancer.
treatment is a new trend of lung cancer diagnosis and treatment, which can effectively improve the survival rate and quality of cancer patients, while reducing unnecessary medical expenses, rational allocation of medical resources, reduce the burden of national health insurance.
Yilong, Life Director of Guangdong Provincial People's Hospital, said in a keynote speech at the forum: "Targeted treatment has entered the era of precision treatment of lung cancer, which is a milestone in the treatment of lung cancer medicine in recent years."
the rise of immunotherapy in recent years has also brought more benefits to lung cancer patients.
with the improvement of targeted treatment, immunotherapy and other precision treatment methods, and constantly move the level of lung cancer diagnosis and treatment forward, these initiatives can bring greater survival benefits to patients.
Professor Wu also mentioned that improving the five-year survival rate is an important goal of tumor prevention and treatment, early screening is the key to reduce lung cancer mortality, multidisciplinary team diagnosis and treatment (MDT) model is the future trend of tumor treatment, but also need to improve drug access.
patients choose drugs, should take into account the effectiveness of the drug, safety, quality of life, and medical insurance or other compensation mechanisms, according to the patient's personal circumstances, tailored to the most appropriate treatment plan.
of innovative drugs with significant efficacy can significantly improve patient choice of treatment drugs, and it is expected that these innovative drugs will be included in health insurance to better benefit lung cancer patients.
Wu Yilong explains that after the start of precision treatment of lung cancer from EGFR-TKI giftoninib, EGFR, ALK and other targeted drug update iterations have evolved from the first generation to the third generation.
When discussing the exploration of better treatment options, Professor Wu cited the three-generation EGFR-TKI target drug Ochitini as an example, and the study confirmed that the first-line use of oxytinib significantly prolonged the disease-free progression survival (PFS) and total survival (OS) in patients with advanced non-small cell lung cancer with EGFR mutation, with a total survival of 38.6 months, more than three years.
Wu also noted that lung cancer targeted therapy studies have spread from common targets to rare targets.
Not only are innovative drugs targeted at targets such as EGFR and ALK, but many studies are exploring targeted treatment options for rare mutant lung cancer in minorities, such as MET, RET, HER2, and other rare target mutations, bringing hope to this group of patients.
The rise and approval of immunotherapy for lung cancer has also brought more benefits to lung cancer patients, not only for the long-term benefits of gene-negative non-small cell lung cancer patients, especially immunosuppressive therapy to Phase III inextricable non-small cell lung cancer patients bring hope for cure, but also immunotherapy has broken the 20-year silence of small cell lung cancer treatment.
Wired Guest - Professor Wu Yilong, Life Director of Guangdong Provincial People's Hospital, focused on patient benefits, improved access to innovative drugs, talked about how to make choices in the course of treatment of lung cancer patients in the face of targeted drugs, Professor Wang Yan, Director of Internal Medicine of the Oncology Hospital of the Chinese Academy of Medical Sciences, said in a statement: "Innovative targeted drugs more and more, follow evidence-based medicine, three generations of targeted drugs and a generation of targeted drugs, survival benefits better."
overall, better innovative drugs should be used at an earlier stage, and in the case of individual patients, drug selection should take into account the efficacy, safety, economy and other factors, can not be generally discussed.
"Professor Wang Yan, Chief Physician of Oncology Hospital, Chinese Academy of Medical Sciences, "Health China Action - Implementation Plan for Cancer Prevention and Control" clearly proposes to adopt comprehensive medical safeguards, improve the dynamic adjustment mechanism of the medical insurance drug catalogue, effectively improve the access to anti-cancer drugs, and reduce the burden of medical treatment for the masses.
how to make innovative drugs truly benefit lung cancer patients is the focus of our government and society.
In order to promote the access of innovative drugs and fully meet the needs of patients, since 2016, China has carried out the provincial health insurance directory, the national health insurance directory and the basic drug catalog update, more and more high-quality anti-cancer drugs can be included in health insurance, drug approval speed is also accelerating.
people can afford innovative drugs, can use high-quality drugs as soon as possible, will move the treatment pass forward, effectively solve the needs of patients, and then improve the overall five-year survival rate of lung cancer, and promote the realization of the goal of a healthy China.
Gu Xuefei, director of the Medical Security Research Office of the Health Development Research Center of the National Health and Health Commission, pointed out that "the State Council's Opinions on Deepening the Reform of the Medical Security System" put forward that by 2030, we will strive to build a multi-level medical security system with basic medical insurance as the main body and medical assistance as the base, supplementing medical insurance, commercial health insurance, charitable donations and mutual development of medical assistance.
the inclusion of innovative drugs in health care requires multiple considerations, including the value of pharmacoeconomics, impact budget analysis, and so on.
of new drugs for cancer has received great attention from the government and all sectors of society in recent years, and the burden on patients has decreased significantly through negotiations and other means.
The key to further improving the accessability of new drugs lies in 'open source savings', on the one hand, to improve the growth mechanism of medical insurance financing, on the other hand, to eliminate the 'god medicine' with unclear efficacy through catalog dynamic adjustment, and to carry out payment method reform to reduce unreasonable resource consumption.
, we can also actively explore financial sharing agreements, pay-per-effects and other innovative payment methods for new drugs.
"" National Health and Health Development Research Center Medical Security Research Office Director Gu Xuefei multi-party help, work together to build a "Healthy China 2030" to help lung cancer patients improve the five-year survival rate, the need for the government, medical institutions, social groups, pharmaceutical enterprises and other sectors of society to work together.
Policies and plans such as the Outline of the "Healthy China 2030" and the Healthy China Action (2019-2030) have provided high housing policy leadership for lung cancer prevention and treatment, and the implementation of the policy requires active cooperation and promotion by local health administration departments at all levels and medical institutions at all levels.
At the same time, social groups and pharmaceutical enterprises, as important forces in building a healthy China, should respond positively to the policy call, support the development of lung cancer diagnosis and treatment in China, help lung cancer patients achieve high-quality long-term survival, and contribute to the ambitious goal of "Healthy China 2030".
AstraZeneta has witnessed and participated in the rapid development of lung cancer diagnosis and treatment in China, said Huang Bin, vice president of AstraZene China and head of corporate affairs and market access at the 2020 China Lung Cancer Summit.
Adhering to the concept of patient-centered, AstraZeneatic has deeply cultivated the field of lung cancer, introduced the world's leading high-quality lung cancer drugs to China, and actively responded to the government, participated in the negotiation of the national health insurance catalogue, volume procurement, and constantly promote the access to innovative anti-cancer drugs.
At the same time, AstraZene is actively exploring the slow-pathological management of lung cancer, relying on provincial and municipal societies, associations, medical institutions and partners to jointly promote the construction of iLCC, and actively carry out public welfare projects for lung cancer screening and prevention, to promote the five-year survival rate of lung cancer, to help 'Healthy China 2030' realization.
," Huang Bin, Vice President of AstraZenecom China and Head of Corporate Affairs and Market Access, has a long way to go to prevent lung cancer, and building a healthy China requires the cooperation of all parties.
the implementation of the "Healthy China 2030" Program Outline, with the macro-promotion of government policies, the medical and health industry has accelerated development, the level of precision diagnosis and treatment has been rapidly improved, and the access to innovative and high-quality medicines has been continuously improved.
together with many parties, to improve the survival rate of cancer patients for 5 years, to achieve long-term survival of patients, to achieve slow management of lung cancer, is gradually becoming a reality, "Healthy China" in the future.
source: medsci!-- content presentation ends -- !-- determine if the login ends.